



Read-through therapeutics reduce cystogenesis in a novel cohort of CRISPR base edited ADPKD organoids

Courtney Vishy – Freedman Lab
University of Washington
Medical Scientist Training Program



Nonsense mutations are severe and common in PKD





ADPKD Mutation Database:

38% of *PKD1* disease-causing mutations are nonsense mutations




50% of *PKD2* disease-causing mutations are nonsense mutations

Novel compounds read-through premature stop codons





Existing animal and kidney organoid models lack mutations amenable to read-through



Nonsense PKD mutations can be modeled in hPSCs



Nonsense kidney organoids form PKD-specific cysts




Nonsense read-through prevents PKD cystogenesis





Read-through is not associated with cytotoxicity

Live/Dead Staining
Calcein AM/**Propidium Iodide**




LDH Release




Conclusions & Future Directions

- Established CRISPR base edited ADPKD organoid cohort with patient targeted nonsense mutations
- Demonstrated read-through as a viable therapeutic approach for reducing cystic burden
- Future work will aim to determine efficacy in vivo

Untreated



Read-Through Compound Treated





**MEDICAL SCIENTIST
TRAINING PROGRAM**
UNIVERSITY of WASHINGTON



Benjamin Freedman

Vijay Modur*

Vasu Badarinarayana*

Matthew Goddeeris*

Daniel Crawford*

Nelly Cruz

Louisa Helms

Sophie Blackburn

Thomas Vincent

Giulia Spennati

Ben Juliar

Nicole Vo

Randy Fennel

Erica Jonlin

Raghava Reddy

Ramila Gulieva



*Eloxx